Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Dinaciclib (SCH 727965) and Ofatumumab for the Treatment of Relapsed and Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL): Results of a Phase 1b/2 Study

Jeffrey Alan Jones, MD MPH, Susan Geyer, PhD, Leslie A. Andritsos, MD, Farrukh Awan, MD MS, Joseph M Flynn, DO, MPH, Kami J. Maddocks, MD, Anissa Bingman, M.S., Amy J. Johnson, PhD, Nyla A. Heerema, PhD, Cathy Brookfield, RN, John C. Byrd, MD, Michael R. Grever, MD

Blood (2014) 124 (21): 329.

https://doi.org/10.1182/blood.V124.21.329.329

Published: 2014

Journal Articles

A Phase I Trial of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Combination with Rituximab (R) and Bendamustine in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma (NHL)

Kristie A. Blum, MD, Beth Christian, MD, Joseph M. Flynn, DO, MPH, Samantha M. Jaglowski, MD, MPH, Jeffrey Alan Jones, MD, MPH, Kami Maddocks, MD, John C. Byrd, MD

Blood (2012) 120 (21): 1643.

https://doi.org/10.1182/blood.V120.21.1643.1643

Published: 2012

Journal Articles

Navitoclax (ABT-263) Plus Fludarabine/Cyclophosphamide/Rituximab (FCR) or Bendamustine/Rituximab (BR): A Phase 1 Study in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL),

Thomas J. Kipps, M.D., Ph.D, Lode J. Swinnen, MD, William G. Wierda, MD, PhD, Jeffrey Alan Jones, MD, MPH, Steven E. Coutre, MD, Mitchell R Smith, MD, PhD, Jianning Yang, PhD, Yue Cui, PhD, Todd Busman, MS, Sari Enschede, MD, Rod Humerickhouse, MD

Blood (2011) 118 (21): 3904.

https://doi.org/10.1182/blood.V118.21.3904.3904

Published: 2011

Journal Articles

Response, Progression-Free Survival, and Overall Survival of Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Treated with Flavopiridol: Impact of Poor Risk Cytogenetic Abnormalities

Jennifer A. Woyach, MD, Amy S. Ruppert, Kristie A. Blum, MD, Jeffrey Alan Jones, MD, MPH, Joseph M. Flynn, DO, MPH, Amy J. Johnson, PhD, Michael R. Grever, MD, John C. Byrd, MD, Nyla A. Heerema, PhD

Blood (2010) 116 (21): 2456.

https://doi.org/10.1182/blood.V116.21.2456.2456

Published: 2010

Journal Articles

Dic(17;18)(p11.2;p11.2) Is a Recurring Abnormality in Chronic Lymphocytic Leukemia Associated with Aggressive Disease.

Jennifer A Woyach, MD, John C. Byrd, MD, John Zhao, MD, PhD, Andrew McFaddin, Amy S Ruppert, Thomas S Lin, MD, PhD, Leslie Andritsos, MD, Kristie A Blum, MD, Joseph M Flynn, DO, MPH, Jeffrey Alan Jones, MD, MPH, Nyla A. Heerema, PhD

Blood (2009) 114 (22): 1233.

https://doi.org/10.1182/blood.V114.22.1233.1233

Published: 2009

Journal Articles

CD19 Targeting of Lymphoid Malignancies by Novel Fc-Domain Engineered Monoclonal Antibody.

Farrukh Awan, MD, MS, Rosa Lapalombella, PhD, Rossana Trotta, PhD, Jonathan P Butchar, Ph.D., Bo Yu, Don Benson, MD, PhD, Carolyn Cheney, Xiaokui Mo, Amy Lehman, Jeffrey Alan Jones, MD, MPH, Joseph M Flynn, David Jarjoura, Robert A. Baiocchi, MD, PhD, John Desjarlais, Susheela Tridandapani, Ph.D., Michael A. Caligiuri, M.D., Natarajan Muthusamy, PhD, John C. Byrd

Blood (2009) 114 (22): 3725.

https://doi.org/10.1182/blood.V114.22.3725.3725

Published: 2009

Journal Articles

Oxaliplatin, Fludarabine, Cytarabine, and Rituximab Combination Therapy Induces High Response Rates in Agressive Chronic Lymphocytic Leukemia (CLL) and Richter's Syndrome (RS).

Apostolia-Maria Tsimberidou, MD, PhD, William Wierda, MD, PhD, William Plunkett, Susan O'Brien, M.D., Thomas J. Kipps, MD, PhD, Jeffrey Alan Jones, MD, MPH, Susan Smith, Annette Jalayer, RN, Hagop M. Kantarjian, MD, Michael Keating, MD

Blood (2009) 114 (22): 3443.

https://doi.org/10.1182/blood.V114.22.3443.3443

Published: 2009

Journal Articles

Attainment of Minimal Residual Disease Negative State Is Crucial for Successful Outcome of Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation in Advanced Chronic Lymphocytic Leukemia (CLL).

Leslie Andritsos, Mehdi Hamadani, Nyla A. Heerema, PhD, Don Benson, Craig C. Hofmeister, MD, William Blum, MD, Joseph Flynn, Jeffrey Alan Jones, MD, Patrick Elder, Thomas S. Lin, Gerard Lozanski, John C. Byrd, Steven Devine

Blood (2008) 112 (11): 2170.

https://doi.org/10.1182/blood.V112.11.2170.2170

Published: 2008

Journal Articles

Rates of Preventable Hospitalization for Ambulatory Care Sensitive Conditions (ACSCs) among Patients with Lymphoid Malignancies (LM)

Jeffrey Alan Jones, MD, MPH, Joseph M Flynn, DO, MPH, John C. Byrd, MD

Blood (2008) 112 (11): 873.

https://doi.org/10.1182/blood.V112.11.873.873

Published: 2008

Journal Articles

Hospital Care of Pathological Vertebral Fracture (PVF) in Multiple Myeloma (MM) Patients: Burden of Illness and Patterns of Care

Jeffrey Alan Jones, MD, MPH, John C. Byrd, MD, Joseph M Flynn, DO, MPH, Craig Hofmeister, MD

Blood (2008) 112 (11): 2409.

https://doi.org/10.1182/blood.V112.11.2409.2409

Published: 2008

NARROW

Dinaciclib (SCH 727965) and Ofatumumab for the Treatment of Relapsed and Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL): Results of a Phase 1b/2 Study

A Phase I Trial of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Combination with Rituximab (R) and Bendamustine in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma (NHL)

Navitoclax (ABT-263) Plus Fludarabine/Cyclophosphamide/Rituximab (FCR) or Bendamustine/Rituximab (BR): A Phase 1 Study in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL),

Response, Progression-Free Survival, and Overall Survival of Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Treated with Flavopiridol: Impact of Poor Risk Cytogenetic Abnormalities

Dic(17;18)(p11.2;p11.2) Is a Recurring Abnormality in Chronic Lymphocytic Leukemia Associated with Aggressive Disease.

CD19 Targeting of Lymphoid Malignancies by Novel Fc-Domain Engineered Monoclonal Antibody.

Oxaliplatin, Fludarabine, Cytarabine, and Rituximab Combination Therapy Induces High Response Rates in Agressive Chronic Lymphocytic Leukemia (CLL) and Richter's Syndrome (RS).

Attainment of Minimal Residual Disease Negative State Is Crucial for Successful Outcome of Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation in Advanced Chronic Lymphocytic Leukemia (CLL).

Rates of Preventable Hospitalization for Ambulatory Care Sensitive Conditions (ACSCs) among Patients with Lymphoid Malignancies (LM)

Hospital Care of Pathological Vertebral Fracture (PVF) in Multiple Myeloma (MM) Patients: Burden of Illness and Patterns of Care

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only